Free Trial
NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

TRACON Pharmaceuticals logo
$0.06 0.00 (0.00%)
(As of 11/14/2024 ET)

About TRACON Pharmaceuticals Stock (NASDAQ:TCON)

Key Stats

Today's Range
$0.03
$0.10
50-Day Range
$0.04
$0.21
52-Week Range
$0.00
$14.75
Volume
37,778 shs
Average Volume
126,396 shs
Market Capitalization
$197,780.00
P/E Ratio
0.02
Dividend Yield
N/A
Price Target
$60.00
Consensus Rating
Hold

Company Overview

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TRACON Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
28th Percentile Overall Score

TCON MarketRank™: 

TRACON Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TRACON Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    TRACON Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about TRACON Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TRACON Pharmaceuticals is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TRACON Pharmaceuticals is 0.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.84.

  • Short Interest

    There is no current short interest data available for TCON.
  • Dividend Yield

    TRACON Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    TRACON Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for TCON.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for TRACON Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for TCON on MarketBeat in the last 30 days.
  • MarketBeat Follows

    8 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 11.61% of the stock of TRACON Pharmaceuticals is held by institutions.

  • Read more about TRACON Pharmaceuticals' insider trading history.
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

Central Bank Abandons USD
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
See More Headlines

TCON Stock Analysis - Frequently Asked Questions

TRACON Pharmaceuticals' stock was trading at $3.5020 at the beginning of 2024. Since then, TCON stock has decreased by 98.3% and is now trading at $0.0593.
View the best growth stocks for 2024 here
.

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) posted its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company earned $0.10 million during the quarter.

TRACON Pharmaceuticals shares reverse split on the morning of Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META).

Company Calendar

Last Earnings
5/14/2024
Today
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TCON
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.00
High Stock Price Target
$60.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+101,080.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-3,590,000.00
Pretax Margin
145.93%

Debt

Sales & Book Value

Annual Sales
$12.05 million
Cash Flow
$1.98 per share
Book Value
($0.37) per share

Miscellaneous

Free Float
3,228,000
Market Cap
$202,213.00
Optionable
No Data
Beta
1.43

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:TCON) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners